NPX-101 is a portable home device for the treatment of moderate to severe depression, boasting more effective and safer outcomes, based on information deposited and received from the Cloud.

Project Information

NPX-101

Grant agreement ID: 728611

DOI 10.3030/728611

Project closed

EC signature date 26 July 2016

Start date 1 June 2016

End date 30 September 2016

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

NEUROPREX EUROPE INC LTD
United Kingdom

Objective

Over 450 million individuals face depression, with over 800,000 suicide deaths per year, delivering a death rate of one person every 40 seconds. These figures are set to increase as estimates put 1 out of 4 individuals in the future to face similar mental disorders at some stage of life.
NPX-101 is the first product line for treating moderate to severe depression, especially the 30% of patients who are currently drug-resistant. It is a patented non-invasive bioelectronic device that delivers Transcranial Magnetic Stimulation (TMS) in the form of a wearable Magnetic Resonance Imaging (MRI) helmet with shield protection. It delivers more precise and deeper energy stimulation, for fuller more effective therapy, removing the side-effects and other treament discomforts with current day treatment. Phase 1 of the SME instrument fits into the overall company plan of NeuroPrex and Omsbar to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the NPX-101. It would importantly help to deduce the quickest routes of distribution and market uptake for its entry-point of the U.K.

Fields of science

• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• social sciences › psychology › psychotherapy
• medical and health sciences › clinical medicine › psychiatry › posttraumatic stress disorder
• engineering and technology › medical engineering › diagnostic imaging › magnetic resonance imaging
• medical and health sciences › basic medicine › neurology › parkinson

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Topic(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-1-2016-2017

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

NEUROPREX EUROPE INC LTD

• Net EU contribution: € 50 000,00
• Address: 72 GREAT SUFFOLK STREET ; SE1 0BL LONDON ; United Kingdom
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  London › Inner London — East › Lewisham and Southwark
• Region: London › Inner London — East › Lewisham and Southwark
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00

Participants (1)

OMSBAR LIMITED

United Kingdom

• Net EU contribution: € 0,00
• Address: 5 THE CHAMBERS, VINEYARD, ABINGDON ; OX14 3PX OXFORDSHIRE
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  South East (England) › Berkshire, Buckinghamshire and Oxfordshire › Oxfordshire
• Region: South East (England) › Berkshire, Buckinghamshire and Oxfordshire › Oxfordshire
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: No data